MAP3K5 and metabolic dysfunction-associated steatohepatitis: Thus, international phase 3 trials evaluating a selective ASK1 inhibitor (selonsertib) among NASH patients with stage 3 (STELLAR3) or cirrhosis (STELLAR4) were initiated (Table 1).